## **ISOBM 2025 Conference Program**

	Sunday, October 12 – Preregistration & Welcome Reception
16:00-17:00	Registration
17:00-19:00	Welcome Reception

	Monday, October 13 – Conference Day 1
08:00-09:00	Registration
09:00-09:30	Opening Ceremony
09:30-10:30	Session 1 – Liquid Profiling by Protein Markers Chairs: S. Holdenrieder, M. Kowalewska A new era of biomarkers: translational strategies to impact cancer care Stefan Holdenrieder (GER) Recent advances in the use of biochemical tumor markers in cancer practice Qing Meng (USA) Integrated diagnostics in oncology: bridging tumor markers with molecular testing and imaging through clinical case studies Tomris Ozben (TUR) Multiplex protein imaging in tumour biology Bernd Bodenmiller (CHE)
10:30-11:00	Coffee + Posters
11:00-12:00	Session 2 – Liquid Profiling by Nucleic Acid Markers Chairs: L. Looijenga, E. Heitzer Liquid insights – ctDNA as a powerful tool for precision oncology Ellen Heitzer (AUT) Cell-free-DNA for multicancer early detection Aviad Zick (ISR) Ultra-sensitive ctDNA profiling in melanoma undergoing immune-checkpoint inhibition Christoffer Gebhardt (GER) Characterization of posttranslational histone modifications on circulating nucleosomes Axel Imhof (GER)
12:00-13:00	Panel Discussion: Early Cancer Detection
13:00 -14:00	Lunch
14:00 -14:30	Keynote 1: <b>Commanding the Future: Will It Be Us or AI?</b> <i>Torsten Haferlach</i> (GER), <i>Chair: Leendert Loojienga</i>
14:30-15:30	Session 3 – Hematological Cancers Chair: T. Haferlach Artificial Intelligence in pathology: transforming diagnosis and discovery Andreas Mock (GER) Al-empowered computational pathology tools for precision oncology Tingying Peng (CHN) Biomarkers in hematology diagnosis with therapy implications Gregor Hoermann (AUT) MRD in hematology: different guidelines and methods with one common goal Constance Baer (GER)
15:30–16:00	Panel Discussion: Artificial Intelligence in Medicine
16:00-16:30	Coffee + Posters
16:30-17:00	Keynote 2: <b>Hope or Horror: Al and Ethics in Medicine</b> <i>Alena Buyx</i> (GER), <i>Chair: Vathany Kulasingam</i>

17:00-18:00	Session 4 – Urological Cancers Chairs: R. Kucera, M. Garrido Prostate cancer risk definition in the screening setting: insights from the PROBASE trial Peter Albers (GER) Predictive and prognostic biomarkers in urological cancers Christopher Poremba (GER) Liquid biopsies for guiding treatment decisions in bladder cancer Iver Nordentoft (DAN) Molecular patterns in testicular cancer Leendert Looijenga (NED)
18:00-19:00	Session 5 – Biobanking and Study Networks (BBMRI-ERIC) Chairs: J. Habermann, M. Kiehntopf BBMRI-ERIC – an exciting resource for biomarker research Jens Habermann (AUT) canSERV – an EU funded project providing cutting edge cancer research services across Europe Manuela Pausan (AUT) Hospital-integrated Biobanking 2.0 Michael Kiehntopf (GER) Biobank network in the Czech Republic Judita Kinkorova (CZR)
19:00-19:30	ISOBM General Assembly
19:30-22:00	Networking Evening (with guided Poster Tour)

	Tuesday, October 14 – Conference Day 2
08:00-08:30	Registration
08:30-09:30	Session 6 – Gynecological Cancers Chairs: V. Kulasingam, J. Osredkar The SURVIVE study – Re-evaluating standard surveillance in early breast cancer survivors using liquid biopsies Sabine Heublein (GER) Multiplex proteomics for tailored ovarian cancer monitoring Vathany Kulasingam (CAN) Prognostic role of CA-125 elimination rate constant (KELIM) in patients with advanced epithelial ovarian cancer Josko Osredkar (SLO) Understanding and treating endometrial cancer in the age of molecular markers Leon Meglic (SLO) Dysbiosis, immunity, and biomarkers: unraveling the molecular landscape of vulvar carcinoma
09:30-10:30	Session 7 – Gastrointestinal Cancers Chairs: V. Heinemann, S. Böck Guiding targeted and immune therapies in gastrointestinal cancers Volker Heinemann (GER) Molecular surgery – a novel concept with clinical implications Martin Angele (GER) Optimization of postoperative treatment in colorectal cancer by plasma ctDNA Kåre Gotschalck (DEN) Circulating autoantibodies in pancreatic cancer: from tumor biology to clinical application Xu Qian (CHN)

10:30-11:00	Coffee + Posters
11:00-12:00	Session 8 – Epigenetic Biomarkers
	Chairs: R. Schneider, M. Sanchez-Carbayo
	Disrupted epigenetics: mechanisms of cancer disease
	Robert Schneider (GER)
	Novel insights from the DNA methylome atlas
	Natanel Loyfer (ISR)  Pirthdating of podiatric tumore
	Birthdating of pediatric tumors     Stefan Pfister (GER)
	Single-molecule, multi-modal, analysis of the epigenetics of plasma isolated nucleosomes
	Efrat Shema (ISR)
12:00-13:00	Panel Discussion: Minimal Residual Disease (MRD) Detection
13:00 -14:00	Lunch
14:00 -14:30	Keynote 3: Liquid Biopsy for Precision Medicine
	Klaus Pantel (GER), Chair: Stefan Holdenrieder
14:30-15:30	Session 9 – Therapy Response Monitoring
	Chairs: N. Normanno, M. Chechlinska
	ctDNA analysis for therapy monitoring and MRD detection
	Nicola Normanno (ITA)
	Molecular monitoring of therapy response in bladder cancer
	Marta Sanchez-Carbayo (ESP)   Implementation of tumor marker-based algorithms in therapy monitoring
	Frederik van Delft (NED)
	Pharmacometric models to support individual dosing
	Oliver Scherf-Clavel (GER)
15:30–16:00	Industry Speed Talks
16:00-16:30	Coffee + Posters
16:30-17:30	Session 10 – Extracellular Vesicles (GSEV)
	Chairs: M. Pfaffl, K. Menck
	Analysis of plasma extracellular vesicles using flow cytometry for cancer diagnostics  Kerstin Menck (GER)
	Detection and monitoring of cancer using activity-based biomarkers from plasma extracellular vesicles
	Jan van Deun (NED)
	Monitoring glioblastoma beyond MRI via serum extracellular vesicle profiling
	Katrin Reiners (GER)
	Identification of new druggable cancer targets by using extracellular vesicles
17.20 10.00	Kathrin Gaertner (GER)
17:30–18:00	Session 11 – Lung Cancer Chairs: H. van Rossum, M. van den Heuvel
	A clinical lab perspective of lung cancer tumor markers
	Huub van Rossum (NED)
	How to use serial multiple serum tumor markers for monitoring non-small cell lung carcinoma
	Michel van den Heuvel (NED)
	Current and future role of liquid biopsy in lung cancer
	Niels Reinmuth (GER)
	Biomarkers for immunotherapy monitoring in lung cancer  David Lang (AUT)
18:30 - 19:00	Poster Speed Talks
19:30 - 22:00	Bavarian Evening (optional)
7.30 22.00	Buvarian Evening (optional)

	Wednesday, October 15 – Conference Day 3
08:00-08:30	Registration
08:30-09:30	Session 12 – Molecular Pathology Chairs: C. Poremba, S. Holdenrieder Immune signals in cancer Jürgen Ruland (GER) Molecular-based classification of cancers Jennelle Hodge (USA) ExLiquid: exploiting liquid biopsies to advance cancer precision medicine Christof Winter (GER) Fragmentomics and multimodal ctDNA diagnostics Tina Moser (AUT)
09:30-10:30	Session 13 – Moving Ahead - Precision Medicine 2.0  Chairs: B. Westphalen, S. Lange  Molecular prevention – where do we stand?  Michael Quante (GER)  Beyond genomics – novel biomarkers on the verge of clinical relevance  Carolin Mogler (GER)  Al biomarkers – transforming personalized healthcare?  Kristian Unger (GER)  Innovative endpoints for trials in precision medicine  Maike Collienne (GER)
10:30-11:00	Coffee + Posters
11:00-12:00	Session 14 – Evidence-based Medicine (WHO IARC IC3R) Chairs: D.Lokuhetty, I. Indave WHO Classification of Tumours (WCT) & International Collaboration for Cancer Classification and Research (IC3R) Dilani Lokuhetty (FRA) Mapping the Evidence for the WHO Classification of Tumours: a Living Evidence Gap Map Iciar Indave (FRA) Breaking down the evidence wall: Making research work for pathology Fiona Campbell (GBR) A new Hierarchy of Evidence for Tumours in Pathology (HETP) Magdalena Chechlinska (POL) Development of a decision tree for accurate coding of study types Elena Beriso (ESP)
12:00-13:00	Panel Discussion: Novel Clinical Study Concepts
13:00-14:00	Lunch
14:00 –14:30	Keynote 4: <b>Effective Treatment Depends on Diagnosis: Why Cancer Classification Matters</b> <i>Ian Cree</i> (GBR), <i>Chair: Magdalena Chechlinska</i>
14:30-15:30	Session 15 – Multimodal and Integrated Diagnostics Chairs: V. Haselmann, C. Winter Integrative liquid profiling for real-time cancer monitoring Verena Haselmann (GER) Integrative advanced imaging for real-time cancer monitoring Matthias Froelich (GER) Diagnosing with words – Large Language Models in medicine Daniel Truhn (GER) LLM-based tumor-agnostic diagnostics Jaqueline Lammert (GER)
15:30-16:00	Industry Speed Talks
16:00-16:30	Coffee + Posters

16:30-17:30 Session 16 – New Biomarkers and Applications (EGTM) Chairs: V. Barak, P. Oehr **EGTM** – past to future activities Vivian Barak (ISR) Circulating tumor DNA as a cancer biomarker: Will it replace standard cancer biomarkers? Michael Duffy (IRL) Non-invasive breath-based cancer screening: Bio-AI hybrid approach Reef Einoch Amor (ISR) Molecular mechanisms and novel therapies to overcome resistance in advanced ER+/HER2- breast cancer Andrea Nicolini (ITA) 17:30-18:30 Session 17 – Standardization and Harmonization (IFCC, GenomeMet) Chairs: H. van Rossum, Q. Meng The IFCC and ISOBM initiative of harmonization of tumor markers Huub van Rossum (NED) Standardization of tumor marker analysis Daan van de Kerkhof (NED) Optimizing biochemical tumor marker testing and interpretation: a CLSI guideline-based approach Qing Meng (USA) The GenomeMET project: approaches for standardization of liquid biopsy and genomic profiling methods Alison Devonshire (GBR) Ensuring accurate patient results for cancer patients - EQA for liquid biopsy testing *Jenni Fairley* (GBR) Results from a pilot EQA for liquid biopsy testing in Germany Marcel Kremser (GER) **Award Ceremony and Closing Session** 18:30-19:00

## With the support of



Silber-Sponsors

**Gold-Sponsor** 



	Please note that only one workshop per time slot can be selected after prior registration!
08:30–10:30	WS 01 – ISOBM: Early Career ISOBM Network for Young Scientists Chairs: H. v. Rossum / M. Kowalewska
	WS 02 – BBMRI-ERIC: Biobanking in Clinical Practice: Quality, international Standards, and Readiness for Research Chair: A. Wutte
	WS 03 – Biostatistical Approaches for Biomarker Validation Chairs: F. Klawonn / P. Oehr
10:30-11:00	Coffee
00	WS 04 – ISOBM: Tips and Strategies to Get your Paper Published Chairs: M. Chechlinska / G. Ricci
11:00-13:00	WS 05 – GSEV: Extracellular Vesicles: Analytics and Clinical Applications Chairs: M. Pfaffl / K. Menck
<del>`</del>	WS 06 – AI-Based Tools for Literature Research and Data Analysis Chairs: J. Adler / I. Trulson
13:00-14:00	Lunch
0	WS 07 – ISOBM: Standardization and Harmonization of Tumor Markers Chairs: H. van Rossum / M. Moore
8	CHUITS, 11, VAIT NOSSUITT IN, INTOTIC
1:00–16:00	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave
14:00–16:00	WS 08 – WHO IARC: Training in Evidence-based Pathology I
16:00-16:30	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave  WS 09 – Methods for ctDNA Analysis in Clinical Practice
16:00–16:30	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave  WS 09 – Methods for ctDNA Analysis in Clinical Practice Chairs: V. Haselmann / A. Bronkhorst
16:00–16:30	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave  WS 09 – Methods for ctDNA Analysis in Clinical Practice Chairs: V. Haselmann / A. Bronkhorst  Coffee  WS 10 – ISOBM: Meet the Experts
	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave  WS 09 – Methods for ctDNA Analysis in Clinical Practice Chairs: V. Haselmann / A. Bronkhorst  Coffee  WS 10 – ISOBM: Meet the Experts Chairs: ISOBM Board  WS 11 – WHO IARC Training in Evidence-based Pathology II
16:00–16:30	WS 08 – WHO IARC: Training in Evidence-based Pathology I Chair: I. Indave  WS 09 – Methods for ctDNA Analysis in Clinical Practice Chairs: V. Haselmann / A. Bronkhorst  Coffee  WS 10 – ISOBM: Meet the Experts Chairs: ISOBM Board  WS 11 – WHO IARC Training in Evidence-based Pathology II Chair: I. Indave  WS 12 – The Pipeline Challenge - NGS Evaluation Tools

Thursday, October 16 – Workshop Day (optional)